glp 1 gip receptor agonist The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Corrination of a GLP-1 Receptor

Effectiveness of acupuncture as auxiliary combined with Western medicine for epilepsy: A systematic review and meta-analysis

They often bring HbA1c levels down by between 0.5 to 1%, although the actual decrease varies from person to person depending largely on their blood sugar at diagnosis and other medications they may be taking

But used wisely, with resistance training, protein optimisation, and patient selection, they may represent the most significant advance in cardiometabolic medicine since statins

This article explores the biology of GLP-1, reviews current and emerging therapies, and examines their implications for the future of drug discovery and development

Patients whose BMI increased had worse outcomes than those with a BMI reduction of 0% to less than 5%